We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microarray-Based Test to Help Better Understand and Detect Complicated UTI Infections

By LabMedica International staff writers
Posted on 05 May 2023

While Urinary Tract Infections (UTIs) are typically straightforward to diagnose and treat, there is a subset of patients for whom this is not the case. More...

These individuals suffer from what are referred to as 'complicated UTIs,' where conventional treatments fall short and a specific combination of antibiotics and treatments tailored to each unique case is required. Understanding the 'microbiome' and its interaction with the infectious pathogen is also a key concern for infectious disease specialists. Now, a single test can identify over 20 organisms and an extensive range of drug-resistant genes, facilitating the development of targeted treatment plans that maximize therapy effectiveness.

PathogenDx’s (Scottsdale, AZ, USA) first UTI assay is built on its unique D3 Array technology, a groundbreaking approach to multiplexed arrays and a crucial asset in the evolution of infectious disease testing. The D3 Array, standing for Dynamic, Dimensional, Detection Technology, bridges the technological gap between traditional PCR-based assays, arrays, and Next-Generation Sequencing (NGS). It offers multiplexed targeted sequence detection that is affordable, quick, and highly accurate and sensitive. The D3 Array is designed to mimic a three-dimensional structure or scaffold, providing a larger surface area than traditional two-dimensional microarrays. This design allows for a higher density of molecular probes attached to the surface, and the sample can move freely within the 3D structure. This movement, similar to a solution-like environment, increases the likelihood of probe-sample binding events, reducing the time needed for hybridization and clinical result reporting.

The D3 Array is quick, shortening the time to results. It can simultaneously provide identification and drug-resistance results in a single test, and detect a wide variety of organisms (bacteria, viruses, fungi), as well as identify drug-resistant genes. This allows for the creation of advanced, multiplexed panels in a single 'well' test. If necessary, the D3 Array can detect over 100 targets in a single reaction, with a single shift time to result. Its unique 3D architecture optimizes the test's speed and sensitivity and enables simplified multiplexed testing. The D3 Array provides multiplexed targeted sequence detection that is cost-effective, quick, and highly accurate and sensitive.

Rapid and precise identification of infectious pathogens is essential to maximize patient care and ensure positive outcomes. Rapid identification of the causative organism and the presence or absence of drug-resistant genes can enhance and guide therapy, promoting effective patient management and preventing serious complications. The D3 Array technology fits perfectly between PCR-based assays, known for their reliable pathogen identification, and NGS sequencing, recognized as a crucial discovery tool. This technology becomes especially valuable when multiple PCR-based assays are needed, which can be costly and time-consuming, or when NGS sequencing goes beyond what is required.

Related Links:
PathogenDx 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Urinalysis Solution
UN-9000
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.